Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
George Bakris MD, FASN, FAHA

George L. Bakris MD, FASN, FAHA

Professor of Medicine and Director, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, Illinois

Dr. Bakris received his medical degree from the Rosalind Franklin Medical School and completed residency in Internal Medicine at the Mayo Graduate School of Medicine where he also completed a research fellowship in Physiology and Biophysics. He then completed fellowships in Nephrology and Clinical Pharmacology at the University of Chicago. From 1988 to 1991, he served as Director of Renal Research at the Ochsner Clinic and had faculty appointments in the Departments of Medicine and Physiology at Tulane University School of Medicine. He later was Professor and Vice Chairman of Preventive Medicine and Director of the Rush University Hypertension Center in Chicago from 1993 until 2006. Currently, he is a Professor of Medicine and Director of the ASH Comprehensive Hypertension Center in the Department of Medicine at the University of Chicago Medicine.

Disclosures

Dr. Bakris is a consultant for Medtronic and Co-PI of SYMPLICITY HTN-3.

Recent Contributions to PracticeUpdate:

  1. Efficacy and Safety of Low-Dose Spironolactone for CKD in Patients With Type 2 Diabetes
  2. Sotagliflozin for Type 2 Diabetes and Severe Renal Impairment
  3. Implications of eGFR Dip Following SGLT2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes
  4. Association Between RAS Blockade Discontinuation and All-Cause Mortality Among Persons With Low eGFR
  5. Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients
  6. Improved Cardiovascular Protection by Initial Two-Drug Fixed-Dose Combination Treatment in Hypertension
  7. Effect of Achieved Systolic Blood Pressure on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus
  8. Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications
  9. MY APPROACH to the Elderly Patient With Resistant Hypertension
  10. Blood Pressure <120/70 mm Hg Is Associated With Better Renal Outcomes in Type 1 Diabetes

Most Read This Week

Recently Updated